Optimising drug treatment for elderly people: The prescribing cascade

British Medical Journal

Volumn 315, Issue 7115, 1997, Pages 1096-1099

  Rochon, Paula A ^a,b,c   Gurwitz, Jerry H ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Department of Medicine ^*  (Canada)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

AGED; DRUG DOSE; DRUG INDUCED DISEASE; DRUG THERAPY; GERIATRIC PATIENT; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY; SYMPTOM; TREATMENT PLANNING;

EID: 0030684063     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.315.7115.1096     Document Type: Short Survey

References (27)

1. Col N, Fanale JE, Kronholm P. The role of medication non-compliance and adverse drug reactions in hospitalizations of the elderly. Arch Int Med 1990;150:841-5.
2. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The cost of adverse drug events in hospitalized patients. JAMA 1997;277: 307-11.
3. Johnson JA, Bootman JL. Drug-related morbidity and mortality: A cost-of-illness model. Arch Intern Med 1995;155:1949-56.
4. Rochon PA, Gurwitz JH. Drug therapy. Lancet 1995;346:32-6.
5. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993;329:2029-32.
6. Meconi M, Taylor L, Martin B, Polgar P. A review: prostaglandins, aging, and blood vessels. J Am Geriatr Soc 1987;35:239-47.
7. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84.
8. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994;272:781-6.
9. Gurwitz JH, Kalish SC, Bohn RL, Glynn RJ, Monane M, Mogun H, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 1997;50:953-9.
10. Avorn J, Gurwitz JH, Bohn RL, Mogun H, Monane M, Walker A. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995;274:1780-2.
11. Solomon DH, Gurwitz JH. Toxicity of nonsteroidal anti-inflammatory drugs in the elderly: Is advanced age a risk factor? Am J Med 1997;102:208-15.
12. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic does of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991;325:87-91.
13. Kovar PA, Allegrante JP, MacKenzie CR, Peterson MGE, Gutin B, Charlson ME. Supervised fitness walking in patients with osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med 1992;116:529-34.
14. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women: the Framingham study. Ann Intern Med 1992;116:535-9.
15. Kelly WN, Schumacher HR Jr, Gout. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 4th ed. Philadelphia: W B Saunders, 1993:1291-336.
16. Fletcher AE. Adverse treatment effects in the trial of the European working party on high blood pressure in the elderly. Am J Med 1991;90:42-3S.
17. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 1993;153:154-83.
18. Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA, et al. Is thiazide-produced uric acid elevation harmful? Arch Intern Med 1987;147:645-9.
19. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med 1967;42:27-37.
20. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). J Am Med Assoc 1991;265:3255-64.
21. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet 1985;i:1349-54.
22. Dalhof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Lancet 1991;338:1281-5.
23. Frishman WH, Bryzinski BS, Coulson LR, DeQuattro VL, Vlachakis ND, Mroczek WJ, et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med 1994;154:1461-8.
24. Ziegler MG, Lernhardt E, Solt-Buzsaki V. Dose response to hydrochlorothiazide in hypertensives receiving a calcium channel blocker. Clin Exp Hypertens 1988;A10:791-800.
25. Andren L, Weiner L, Svensson A, Hansson L. Enalapril with either a "very low" or "low" dose of hydrocholrothiazide is equally effective in essential hypertension: a double-blind trial in 100 hypertensive patients. J Hypertens 1983;1(suppl 2):384-6.
26. Koller W, O'Hara R, Weiner W, Lang A, Nutt J, Agid Y, et al. Relationship of aging to Parkinson's disease. Adv Neurol 1987;45:317-21.
27. Martilla RJ, Rinne UK. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand 1976;53:81-102.